Cargando…
Monoclonal antibodies in the management of asthma: Dead ends, current status and future perspectives
Patients with moderate-to-severe asthma may now be treated using a variety of monoclonal antibodies that target key inflammatory cytokines involved in disease pathogenesis. Existing clinical data on anti-IgE, anti-IL-5 and other immunological pathways indicate these therapies to offer reduced exacer...
Autores principales: | Kardas, Grzegorz, Panek, Michał, Kuna, Piotr, Damiański, Piotr, Kupczyk, Maciej |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9763885/ https://www.ncbi.nlm.nih.gov/pubmed/36561741 http://dx.doi.org/10.3389/fimmu.2022.983852 |
Ejemplares similares
-
Biological Therapies of Severe Asthma and Their Possible Effects on Airway Remodeling
por: Kardas, Grzegorz, et al.
Publicado: (2020) -
Clinical profiles of patients referred for biological therapy and major limitations in the qualification paths in a specialist asthma centre
por: Damiański, Piotr, et al.
Publicado: (2023) -
Targeting the PGD(2)/CRTH2/DP1 Signaling Pathway in Asthma and Allergic Disease: Current Status and Future Perspectives
por: Kupczyk, Maciej, et al.
Publicado: (2017) -
Role of Platelet-Derived Growth Factor (PDGF) in Asthma as an Immunoregulatory Factor Mediating Airway Remodeling and Possible Pharmacological Target
por: Kardas, Grzegorz, et al.
Publicado: (2020) -
Primary non-adherence to inhaled medications measured with e-prescription data from Poland
por: Kardas, Grzegorz, et al.
Publicado: (2020)